Liver Disease Treatment Market by Product Type, Distribution Channel, End User 2024-2032
                     Global Liver Disease 
Treatment Market 
Research and Forecast 
Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
Acco r d ing  t o  t he  l a t es t  r epo r t  by  I M ARC  G r o up ,  t i t l ed  " L i v er  D i seas e  Tre a t me nt  
M ar ke t :  G l ob a l  I ndu st ry  T rend s ,  Shar e ,  S i ze ,  G row t h ,  O pp or t u n i t y  and  Fo rec as t  
2024 - 203 2 , "  t he  g lob a l  l i ve r  d i sea se  t r e a t m en t  m ar ke t  s i ze  r ea ched  US $  23 . 8  B i l l i on  
i n  2 023 .
Report L ive r  d i sea se  i s  gene r a l l y  ca used  due  t o  i n he r i t ed  cond i t i ons ,  i n f ec t i o ns ,  m isu se  o f  a l coh o l  a nd  obes i t y .  Th ese  c ond i t i ons  us ua l l y  a f f e c t  an d  dam age  t he  f unc t i on ing  o f  
t he  l i ve r  w h i l e  caus ing  va r i o us  ch r o n i c  c ond i t i ons ,  i nc lud ing  canc e r ,  c i r r ho s i s  a nd  
Highlight and l i ve r  f a i l u r e .  S om e  o f  i t s  com m on  s ym p t o m s  inc lude  abd om i na l  pa in ,  f a t i gue ,  naus ea  
o r  v om i t in g ,  e dem a an d  cha nge  i n  t he  co lo r  o f  s t oo l  o r  u r i ne .  
L i ve r  d i s ease  t r ea t m e n t  i nvo lv es  va r i o us  t he r ap eu t i c  t ec hn ique s  t h a t  a id  i n  
Description de t o x i f i ca t i on ,  op t im iz in g  l i ve r  f un c t i on ing ,  p r o t e c t i ng  l i ve r  c e l l s  f r om  i n f l am m at i on ,  
im p r oved  m e t ab o l i sm  a nd  i nc r e as ing  en zym e  and  b i l e  p r oduc t i on .  M or e ove r ,  e a r l y  
de t e c t i on  a nd  t r ea t m e n t  o f  t he se  con d i t i ons  he lp  i n  p r e ven t i ng  f u r t he r  da m ag e  t o  t he  
l i ve r  wh i l e  p r om o t ing  ove r a l l  l i v e r  he a l t h .
Reque st  f o r  a  P DF  s ampl e  o f  t h i s  repor t :  
h t t p s : / / www. im ar c g r ou p . com / l i ve r - d i se ase - t r ea t m en t - m a r ke t / r equ es t sa m p l e
Report Description
G lo b a l  L iv e r  D is e a s e  T r e a t m e n t  M a r k e t  T r e n d s :
T h e  g l o b a l  m a r k e t  i s  p r i m a r i l y  d r i v e n  b y  t h e  i n c r e a s i n g  p r e v a l e n c e  o f  l i v e r  d i s e a s e s  a m o n g  t h e  m a s s e s .  C o u p l e d  w i t h  t h e  r i s i n g  
g e r i a t r i c  p o p u l a t i o n  t h a t  i s  h i g h l y  s u s c e p t i b l e  t o  d e v e l o p i n g  c h r o n i c  l i v e r  c o n d i t i o n s ,  t h i s  i s  f a v o r a b l y  i m p a c t i n g  t h e  m a r k e t  
g r o w t h .  M o r e o v e r ,  e x t e n s i v e  r e s e a r c h  a n d  d e v e l o p m e n t  ( R & D )  a c t i v i t i e s  c o n d u c te d  i n  m e d i c a l  s c i e n c e  a n d  b i o te c h n o l o g y  a r e  
p r o v i d i n g  a n  i m p e t u s  t o  t h e  m a r k e t  g r o w th .  F u r t h e r m o r e ,  v a r i o u s  t e c h n o l o g i c a l  a d v a n c e m e n t s  a c r o s s  t h e  h e a l t h c a r e  s e c to r ,  s u c h  
a s  t h e  i n t r o d u c t i o n  o f  g e n e  t h e r a p y  a n d  b i o a r t i f i c i a l  l i v e r ,  a r e  p o s i t i v e l y  i n f l u e n c i n g  t h e  m a r k e t  g r o w t h .  
I n  a d d i t i o n  t o  t h i s ,  i n c r e a s i n g  i n v e s tm e n t s  a n d  f u n d i n g  t o  u p g r a d e  t h e  e x i s t i n g  h e a l t h c a r e  i n f r a s t r u c t u r e  a r e  c o n s i d e r e d  t o  b e  
m a j o r  g r o w t h - i n d u c i n g  f a c t o r s .  A p a r t  f r o m  t h i s ,  r a p i d  d i g i t i z a t i o n  a n d  t h e  p e n e t r a t i o n  o f  h i g h - s p e e d  i n t e r n e t  c o n n e c t i v i t y  a n d  
s m a r t p h o n e s  h a v e  e n a b l e d  e a s y  a c c e s s  t o  m e d i c a l  f a c i l i t i e s  f o r  t h e  m a s s e s ,  t h e r e b y  c r e a t i n g  a  p o s i t i v e  o u t l o o k  f o r  t h e  m a r k e t .  
O th e r  f a c t o r s ,  i n c l u d i n g  t h e  c h a n g i n g  l i f e s t y l e  p a t t e r n s ,  i n c r e a s i n g  c o n s u m p t i o n  o f  a l c o h o l  a n d  t h e  r i s i n g  a w a r e n e s s  r e g a r d i n g  t h e  
h a r m f u l  e f f e c t s  o f  l i v e r  d i s e a s e s  a m o n g  t h e  m a s s e s ,  a r e  f u r t h e r  c o n t r i b u t i n g  t o  t h e  m a r k e t  g r o w th .
L o o k in g  f o r w a r d ,  t h e  m a r k e t  i s  a n t i c ip a t e d  t o  r e a c h  a  v a l u e  o f  U S $  3 9 .4  B i l l i o n  b y  2 0 3 2 ,  e x h i b i t i n g  a  C A G R  o f  5 . 7 %  d u r in g  
2 0 2 4 - 2 0 3 2 .
V ie w  R e p o r t  T O C ,  F i g u r e s  a n d  T a b l e s :  h t t p s : / / w w w . i m a r c g r o u p . c o m / l i v e r - d is e a s e - t r e a t m e n t - m a r k e t
Breakup by Treatment Type:
• Antiv iral  Drugs
• Immunosuppressants
• Vaccines
• Immunoglobul ins
• Cort icosteroids
• Targeted Therapy
Report 
• Chemotherapy
Segmentation
Breakup by Disease Type:
• Hepatit is
• Autoimmune Diseases
• Non-alcohol ic Fatty Liver Disease (NAFLD)
• Cancer
• Genetic Disorders
• Others
Breakup by End User:
• Hospitals
• Ambulatory Surgical  Centers
• Others
Report 
Segmentation Breakup by Region:
• North America
• Asia-Pacifi c
• Europe
• Latin America
• Middle East and Afr ica
• Abbott  Laborator ies
• AbbVie  Inc.
• Astel las  Pharma Inc .
• Bristol -Myers Squibb Company
• El i  L i l ly  and Company
Competitive • Emergent B ioSolut ions Inc.
Landscape • F.  Hoff mann-La Roche AG
• Gilead Sciences Inc.
with Key • GlaxoSmithKl ine p lc
Players • Merck & Co. Inc.
• Novart is  AG
• Pfi zer Inc.
• Sanofi  S.A.
• Takeda Pharmaceut ica l  Company L imited
• Viatr is  Inc.
What was the size of the global liver disease treatment 
market in 2023?
What is the expected growth rate of the global liver 
disease treatment market during 2024-2032?
What are the key factors driving the global liver disease 
treatment market?
Key 
What has been the impact of COVID-19 on the global 
Questions liver disease treatment market?
Answered in What is the breakup of the global liver disease treatment market based on the treatment type?
the Report What is the breakup of the global liver disease treatment market based on the disease type?
What is the breakup of the global liver disease 
treatment market based on the end user?
What are the key regions in the global liver disease 
treatment market?
Who are the key players/companies in the global liver 
disease treatment market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  L i v e r  D i s e a s e  T r e a t m e n t  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  T r e a t m e n t  T y p e
    6 . 1     A n t i v i r a l  D r u g s
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     I m m u n o s u p p r e s s a n t s
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
    6 . 3     V a c c i n e s
        6 . 3 . 1  M a r k e t  T r e n d s
        6 . 3 . 2  M a r k e t  F o r e c a s t
       
    6 . 4     I m m u n o g l o b u l i n s
        6 . 4 . 1  M a r k e t  T r e n d s
        6 . 4 . 2  M a r k e t  F o r e c a s t
    6 . 5     C o r t i c o s t e r o i d s
        6 . 5 . 1  M a r k e t  T r e n d s
        6 . 5 . 2  M a r k e t  F o r e c a s t
    6 . 6     T a r g e t e d  T h e r a p y
        6 . 6 . 1  M a r k e t  T r e n d s
        6 . 6 . 2  M a r k e t  F o r e c a s t
    6 . 7     C h e m o t h e r a p y
        6 . 7 . 1  M a r k e t  T r e n d s
        6 . 7 . 2  M a r k e t  F o r e c a s t
Table of 7    M a r k e t  B r e a k u p  b y  D i s e a s e  T y p e    7 . 1     H e p a t i t i s
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
Contents     7 . 2     A u t o i m m u n e  D i s e a s e s        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
    7 . 3     N o n - a l c o h o l i c  F a t t y  L i v e r  D i s e a s e  ( N A F L D )
        7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
    7 . 4     C a n c e r
        7 . 4 . 1  M a r k e t  T r e n d s
        7 . 4 . 2  M a r k e t  F o r e c a s t
    7 . 5     G e n e t i c  D i s o r d e r s
        7 . 5 . 1  M a r k e t  T r e n d s
        7 . 5 . 2  M a r k e t  F o r e c a s t
    7 . 6     O t h e r s
        7 . 6 . 1  M a r k e t  T r e n d s
        7 . 6 . 2  M a r k e t  F o r e c a s t     
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
h t t p s : / / w w w. i m a rc g ro u p . c o m / l i ve r- d i s e a s e - t re a t m e n t - m a r ke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: